Abstracts tagged "Biologic agents"

Abstract Number: 2524 • 2015 ACR/ARHP Annual Meeting
Longterm Follow-up of Children Born to Mothers with Chronic Arthritides and Exposed to Anti-TNF Alfa Agents during Pregancy and Breastfeeding: A Case-Control Study
Rossella Reggia¹, Laura Andreoli¹, Chiara Bazzani¹, Maria Grazia Lazzaroni¹, Giovanna Mazza¹, Michele Agosti¹, Roberto Gorla², Marco Taglietti², Andrea Lojacono³, Mario Motta⁴ and Angela Tincani⁵, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Neonatal Intensive Care Unit, University and Spedali Civili of Brescia, Brescia, Italy, ⁵Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Anti-TNFalfa agents have been used to control disease activity of patients with Chronic Arthritides (Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis) during the wash-out period…
Abstract Number: 2896 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Dominique Baeten¹, Jurgen Braun², Joachim Sieper³, Maxime Dougados⁴, Atul A. Deodhar⁵, Xenofon Baraliakos⁶, Brian Porter⁷, Yankun Gong⁸ and Hanno Richards⁹, ¹1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, Herne, Germany, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Paris-Descartes University, Paris, France, ⁵Oregon Health and Sciences University, Portland, OR, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Beijing Novartis Pharma Co. Ltd., Beijing, China, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks (wks) in the randomized, double-blind, placebo (PBO)-controlled,…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
Abstract Number: 1942 • 2014 ACR/ARHP Annual Meeting
Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark⁴, ¹Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom, ⁴Department of Immunology and Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose The B cell-associated receptor, CD22, functions to regulate adhesion and signaling through both the B cell receptor (BCR) and Toll-like receptors (TLRs) expressed in…
Abstract Number: 494 • 2014 ACR/ARHP Annual Meeting
Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Chia-Chen Teng², Tao He², Jianwei Leng³, Chao-Chin Lu², Derek Tang⁴, Neel Shah⁵, David J. Harrison⁴ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ⁴Amgen Inc., Thousand Oaks, CA, ⁵1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA
Background/Purpose: An algorithm based on administrative claims data (in lieu of clinical measures) was validated using data from the Veteran’s Affairs (VA) Rheumatoid Arthritis (RA)…
Abstract Number: 2512 • 2014 ACR/ARHP Annual Meeting
Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry
Vittorio Grosso¹, Roberto Gorla², Piercarlo Sarzi-Puttini³, Fabiola Atzeni⁴, Raffaele Pellerito⁵, Enrico Fusaro⁶, Giuseppe Paolazzi⁷, Pier Andrea Rocchetta⁸, Ennio Giulio Favalli⁹, Antonio Marchesoni¹⁰ and Roberto Caporali¹¹, ¹Division of Rheumatology,, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ²Reumatologia, Spedali Civili, Brescia, Italy, ³Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁵Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁶Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁷Rheumatology, Santa Chiara Hospital, Trento, Italy, ⁸Struttura di Reumatologia A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Rheumatology, Gaetano Pini Institute, Milano, Italy, ¹¹Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Golimumab therapy retention rates in patients with rheumatoid arthritis and seronegative spondyloarthritis: data from the Italian LORHEN registry Background/Purpose The efficacy of Golimumab (GLM) treatment…
Abstract Number: 1868 • 2014 ACR/ARHP Annual Meeting
Can DAS 28 at 3 Months after the 1^st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients?
Tomohiro Kubota¹, Syuji Takei², Tsuyoshi Yamatou³, Tomokazu Nagakura⁴, Hiroyuki Imanaka³, Yukiko Nonaka³, Tomoko Takezaki³, Harumi Akaike³ and Mio Matsuura⁵, ¹8-35-1 Sakuragaoka, Kagoshima University Hospital, Kagoshima City, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Kagoshima University, Kagoshima-Shi, Japan
Background/Purpose: To avoid the progression of joint damage, early decision making is important in JIA patients who failed to achieve sustainable clinical remission by…
Abstract Number: 491 • 2014 ACR/ARHP Annual Meeting
Do Patients with Congestive Heart Failure Treated with Biologics for RA Have a Lower Risk of Fatal Outcome of Serious Infections?
Anja Strangfeld¹, Adrian Richter¹, Yvette Meissner¹, Matthias Schneider², Michael Zaenker³, Wolfgang Ochs⁴, Thomas Klopsch⁵, Angela Zink⁶ and Joachim Listing¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ³Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany, ⁴Rheumatologist in private practice, Bayreuth, Germany, ⁵Rheumatologist in private practice, Neubrandenburg, Germany, ⁶German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Patients with multimorbid conditions are at high risk of developing serious infections (SI) and of premature mortality. TNF inhibitors increase the infection risk (1)…
Abstract Number: 2511 • 2014 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry
Jose A Gomez-Puerta^1,2, M. Victoria Hernández¹, Fernando Sanchez-Alonso³, Kazuki Yoshida^2,4, Raimon Sanmarti¹, Daniel H Solomon², Juan J Gomez-Reino⁵ and On behalf of BIOBADASER 2.0 study group³, ¹Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, Boston, MA, ³Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁴Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁵Hospital Clinico Universitario at the Universidad de Santiago de Compostela, Santiago, Spain
Background/Purpose: Remission is considered an achievable goal for many patients under biologic therapies. However, currently there is limited information about predictors of discontinuation of biologic…
Abstract Number: 1881 • 2014 ACR/ARHP Annual Meeting
Patients Who Fail Biologics Are More Likely to Have Concomitant Fibromyalgia
Robert S. Katz¹ and Jessica L. Polyak², ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: One area not assessed by studies to evaluate the efficacy of new medications in patients with inflammatory arthritis is whether the patient may have…
Abstract Number: 490 • 2014 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis â€“ an Interim Analysis
Stephen Oakley^1,2,3, Niloofar Esmaili⁴, Gabor Major⁴, David Mathers^4,5, Siva Ratnarajah⁶, John van der Kallen⁵, Mark Collins⁶, Marc Toh⁶ and John Glass⁴, ¹Dept of Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Clinical Trials Unit, Hunter Medical Research Institute, Newcastle, Australia, ⁴Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ⁵Rheumatology, Georgetown Arthritis Centre, Newcastle, Australia, ⁶Rheumatology, Private Practice, Newcastle, Australia
Background/Purpose Rheumatoid arthritis (RA) is associated with elevated cardiovascular (CV) risk not explained by traditional risk factors. Increased CV risk may develop prior to the…
Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
M. Victoria Hernández¹, Andrea Cuervo¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…
Abstract Number: 1842 • 2014 ACR/ARHP Annual Meeting
High Rates of Failure after Biological DMARD Discontinuation While in Remission in a Japanese Multi-Center Registry
Kazuki Yoshida^1,2, Mitsumasa Kishimoto³, Helga Radner^1,4, Kazuo Matsui⁵, Masato Okada⁶, Yukihiko Saeki⁷, Daniel H. Solomon¹ and Shigeto Tohma⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Department of Rheumatology, Kameda Medical Center, Kamogawa City, Japan, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁶Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁷Department of Clinical Research, Osaka-Minami Medical Center, Osaka, Japan, ⁸Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Since the introduction of biological disease-modifying antirheumatic drugs (bDMARDs) and tight control strategies, remission has become a more feasible treatment target for an increasing…
Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
Abstract Number: 2473 • 2014 ACR/ARHP Annual Meeting
Post-Marketing Surveillance of Efficacy and Safety of Tacrolimus Add-on Therapy in Japanese Rheumatoid Arthritis Patients Who Failed to Show an Adequate Response to Biological Dmards : Interim Analysis
Tsutomu Takeuchi¹ and Kota Ishida², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ²Astellas Pharma Inc., Tokyo, Japan
Background/Purpose: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T cell activation by specifically inhibiting calcineurin, and it is widely administered following organ transplantation. TAC…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].